In Vivo |
Mahanimbine (2-4 mg/kg; p.o.; daily for 12 weeks) prevents HFD-induced weight gain in mice (male and female)[1]. Mahanimbine prevented HFD-induced hyperlipidemia and fat accumulation in adipose tissue and liver along with the restricted progression of systemic inflammation and oxidative stress[1]. Mahanimbine treatment improves glucose clearance and upregulates the expression of insulin responsive genes in liver and adipose tissue[1]. Animal Model: Swiss albino mice (7-8 weeks old, both sex)[1] Dosage: HFD+LD (2 mg/kg of body weight of mahanimbine), HFD+HD (4 mg/kg of body weight of mahanimbine); Administration: Oral suspension; daily for 12 weeks Result: Male HFD+LD and HFD+HD groups showed 51.70±6 3.59% and 47.37±3.73% weight gain, respectively, as compared with 71.02±6 6.04% in HFD fed mice whereas female HFD+LD and HFD+HD groups showed 24.31±1.68% and 25.10±2.61% weight gain as compared with HFD group with 36.69±3.60% of weight gain.
|